EEG / EMG in Maryland

LKC Technologies is a specialized medical device manufacturer headquartered in Germantown, Maryland, with over 45 years of expertise in visual electrophysiology. The company designs and manufactures FDA-cleared, portable electroretinography (ERG) and visual evoked potential (VEP) testing systems for both human and veterinary ophthalmology applications. LKC's flagship product, the RETeval®, is a handheld, battery-powered, non-mydriatic ERG/VEP device that enables objective functional assessment of retinal health and visual pathways. The company also offers the UTAS™ mf/PERG system for comprehensive multifocal and pattern ERG/VEP testing, and RETevet™ for veterinary ophthalmology. These devices serve optometrists, ophthalmologists, and research institutions globally, with particular applications in diabetic retinopathy monitoring, glaucoma assessment, inherited retinal disease diagnosis, and pediatric vision evaluation. LKC holds ISO 13485:2016 certification and FDA registration, with products supported by over 250 peer-reviewed publications.

BrainScope is a commercial-stage medical neurotechnology company specializing in AI-powered EEG-based diagnostic solutions for brain health. Founded in 2006 and based in Rockville, Maryland, BrainScope has developed a proprietary platform that applies machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. The company created the first FDA-cleared AI/Machine Learning medical device in neurology and holds a portfolio of 83 issued patents. BrainScope's primary offering is a hand-held, point-of-care device for assessing mild traumatic brain injuries (mTBI), structural brain bleeds, and concussions in under 20 minutes. The technology has demonstrated ~50% reduction in unnecessary head CT scans and substantial reductions in emergency department patient length of stay. Beyond head injury assessment, BrainScope is developing novel biomarkers for stroke detection, early Alzheimer's detection (with dementia risk prediction up to 7 years before initial diagnosis), and other CNS indications. The company serves acute care settings, hospitals, emergency departments, and pharmaceutical/drug development partners.